

***Fiscal Year 2023 Department of Defense Rare Cancer Research Program (RCRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Concept Award (CA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT9425-23-RCRP-CA</p>	<p>Investigators at or above the level of postdoctoral fellow</p>	<ul style="list-style-type: none"> <li>• Supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers.</li> <li>• Supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of rare cancers or develop an innovative and novel course of investigation</li> <li>• Submission must address at least one of the FY23 Focus Areas.</li> <li>• Preliminary data are not required</li> <li>• Clinical trials are not allowed.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$100,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 14, 2023 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> August 25, 2023 11:59 p.m. ET</p>
<p><b>Idea Development Award (IDA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT9425-23-RCRP-IDA</p>	<p>Investigators at or above the level of Assistant Professor</p>	<ul style="list-style-type: none"> <li>• Supports new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.</li> <li>• Supports research supported by preliminary data that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from rare cancers.</li> <li>• <b><i>Preliminary data with disease-specific rationale (may include correlative studies to ongoing clinical research) to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of the proposed rare cancer type(s)/subtype(s) under study.</i></b></li> <li>• Submission must address at least one of the FY23 Focus Areas.</li> <li>• Clinical trials are not allowed.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$350,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 26, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 29, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Resource and Community Development Award (RCDA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT9425-23-RCRP-RCDA</p>	<p>Investigators at or above the level of Assistant Professor</p>	<ul style="list-style-type: none"> <li>• Supports development of research platforms to share resources, knowledge, and information to facilitate collaboration among stakeholders such as researchers, patients, caregivers, clinicians, and other members of the rare cancers' community.</li> <li>• Supports platform development or infrastructure that can be applied to multiple rare cancers.</li> <li>• Applications to the RCDA funding opportunity are required to include patient advocates who are involved with patient advocacy organization(s). The research team must include at least two rare cancer patient advocates as early and integral partners throughout the planning and implementation of the research project, including development of the research question, project design, oversight, and evaluation.</li> <li>• Preliminary data are not required but may be included (translational research and clinical studies may be included).</li> <li>• Submission must address the FY23 Platform Development Focus Areas.</li> <li>• Clinical trials are not allowed.</li> <li>• <i>Pre-application submission is required; application submission is by invitation only.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$800,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 26, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 29, 2023 11:59 p.m. ET</p>